Regeneron Pharmaceuticals Stock News

BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.

BioNTech SE (NASDAQ: BNTX ) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with … Full story available on Benzinga.com

BioNTech SE and Regeneron Pharmaceuticals Inc. said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron''s Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma. The companies already have an agreement evaluating this combination in patients with advanced melanoma. Both companies have generated billions of dollars in revenue from COVID-19 vaccines and treatments over the course of the pandemic. So far this year, BioNTech''s stock has tumbled 51.0%, while shares of Regeneron are down 2.0%. The S&P 500 has declined 8.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

On Tuesday, German vaccine maker BioNTech (BNTX) announced an expansion of its strategic collaboration with Regeneron (REGN) to add advanced non-small cell lung cancer ((NSCLC))…

BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advance

These three stocks are solid value picks in different areas of healthcare.

These companies are banking more than 30% of their revenue as profit.

Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Although Piper Sandler is maintaining an outperform rating for Regeneron Pharmaceuticals (REGN), a new survey is providing concern for the competitive outlook for the AMD treatment Eylea.

Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.

This recently approved generic drug could benefit 5% to 15% of the overall population.

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.